PCM
ALNY icon

Price Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Price Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-2,213
Closed -$231K – 11
2015
Q1 		$231K Buy
+2,213
New +$224K 0.14% 209

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Price Capital Management's ALNY Position: Q2 2015 in Review

Price Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q2 2015, closing a stake of 2,213 shares — an estimated $231K sold.

Price Capital Management first reported a position in ALNY in Q1 2015 and held it in 1 quarter. The position peaked at $231K in Q1 2015. 277 funds tracked by Wall St. Rank hold ALNY as of Q2 2015.

  • Price Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Price Capital Management sold 2,213 Alnylam Pharmaceuticals shares in Q2 2015, an estimated $231K.
  • Price Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Price Capital Management's Alnylam Pharmaceuticals position peaked at $231K in Q1 2015.
  • 277 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2015.

Based on Price Capital Management's 13F filing for Q2 2015.